Epilepsy Pipeline Conference 2009 to Showcase Cutting-Edge Therapies in Development and Advances in the Treatment of Epilepsy

Middleburg, VA, April 13, 2009 – The Epilepsy Therapy Project today announced that more than 25 emerging companies as well as leading biotechnology and pharmaceutical investors and industry executives will gather to focus on preclinical and clinical development strategies and opportunities at the Epilepsy Pipeline Conference 2009. The one-day Epilepsy Pipeline Conference 2009 will showcase the most innovative therapeutic approaches currently in development for the treatment of epilepsy. The conference will take place Friday, April 17, 2009 at the Biltmore Hotel in Coral Gables, Florida, in conjunction with the Antiepileptic Drug Trials X (AED-X) conference.

“With more than three million patients in the US alone, epilepsy represents a huge and significantly unmet medical need. We are excited to see such a high caliber group of scientific entrepreneurs presenting the latest insights and approaches to addressing epilepsy, as well as other central nervous system disorders,” said Joyce Cramer, President of Epilepsy Therapy Project. “In addition to our commitment to funding clinical research, the Epilepsy Therapy Project plays a critical role in bringing together scientific entrepreneurs with venture capital and public equity investors and pharmaceutical industry partners. Through the Epilepsy Pipeline Conference 2009 we are creating a forum to drive innovation in the discovery and development of new treatments that we hope will ultimately eradicate seizures in the next decade.”

Pipeline conference attendees will hear the latest insights from research, clinical and industry leaders, supporting informed decisions about investment in epilepsy therapy development and broader central nervous system (CNS) therapeutic areas. Investors and industry business development executives are encouraged to attend.

"With well-characterized mechanisms, therapeutic approaches, functional models and defined clinical endpoints, epilepsy is gaining recognition as an excellent starting point for companies seeking to develop new CNS diagnostics and therapeutics," said Omar Amirana, MD, Partner at Oxford Bioscience Partners. "Forums such as this provide investors, research experts and industry leaders with an opportunity to understand the major scientific and clinical advances taking place in CNS and help optimize our collective investments in future therapies."

Presenting companies at the one-day conference include: Marinus Pharmaceuticals, Sepracor, Valeant Pharmaceuticals, Icagen, NeuroTherapeutics Pharma, Neuropace and SierraNeuro, among others. In addition, the conference will feature a dynamic panel discussion between private and public investors as well as commercial business development executives on financing new epilepsy and CNS therapies.

Conference Highlights Will Be Available on http://professionals.epilepsy.com

Highlights from the conference will be summarized in a webcast event on epilepsy.com, the Epilepsy Therapy Project’s website for professionals and patients.

“As a clinician, I think the collaboration of investors, foundations and industry can provide the critical catalyst in supporting advances in this field,” said Orrin Devinsky, MD, New York University Epilepsy Center. “Forums such as the Epilepsy Pipeline Conference 2009 have the potential to increase the pace in developing and commercializing important new treatment options. I look forward to the opportunity to be updated on the latest innovations in the pipeline with the potential to ultimately benefit patients.”

The conference is organized by the Epilepsy Therapy Project and Epilepsy Study Consortium, 501( c) (3) non-profit organizations, New York University, and University of Pennsylvania. Epilepsy Therapy Project is a recognized leader in advancing new therapies for people epilepsy.

About the Epilepsy Therapy Project
The Epilepsy Therapy Project is a 501 (c) (3) not-for-profit organization dedicated to overcoming the funding gaps that slow the progress of new therapies from the lab to the patient. Epilepsy Therapy Project seeks to improve incentives and encourage commercial investment in new therapies. Acting as both a catalyst and clearinghouse for innovative research and the early commercialization of new therapies, the Epilepsy Therapy Project brings together financial resources, scientific insights and business expertise from leading academic and commercial industry participants. If you are a physician or a patient, please visit our website at www.epilepsy.com. For more information on how to support innovative epilepsy therapies in development, please visit www.epilepsy.com/epilepsy_therapy_project.

For more information, contact Joyce Cramer at joyce@epilepsytherpayproject.org

# # #

Epilepsy Pipeline Conference 2009


Friday, April 17th in Conjunction with the 10th Antiepileptic Drugs Conference
Biltmore Hotel, 1200 Anastasia Avenue, Coral Gables, Florida 33134


Phase III
8:15-8:30 Responsive
Neurostimulation System
Neuropace Martha Morrell, MD
8:30-8:45 Brivaracetam UCB Philipp von Rosenstiel, MD
8:45-9:00 Carisbamate Johnson & Johnson PRD Gerald Novak, MD
9:00-9:15 Eslicarbazepine Sepracor Mark Versavel, MD
9:15-9:30 Intranasal Midazolam Ikano Therapeutics Jeff Edelson, MD
9:30-9:45 Modif Release
Oxcarbazepine
Supernus Paolo Baroldi, MD, PhD
9:45-10:00 Retigabine Valeant Pharmaceuticals Hank Mansbach, MD
10:00-10:20 BREAK
10:20-10:35 Vigabatrin Lundbeck Stephen Sagar, MD
10:35-10:50 Clobazam Lundbeck Mark Weinberg, MD
Phase II
10:50-11:05 Ganaxalone Marinus Pharmaceuticals Julia Tsai, PhD
11:05-11:20 ICA-105665 Icagen Greg Rigdon, PhD
11:20-11:35 Perampanel (E2007) Eisai David Squillacote, MD
11:35-11:50 T2000 Taro Pharmaceutical Industries Daniel Moros, MD
111:55-12:10 YKP3089 SK Life Sciences S. James Lee, PhD
12:10-12:25 VPA: 2nd Generation Drugs Hebrew Univ. of Jerusalem Meir Bialer, PhD, MBA
12:25-1:25 Lunch
Early-Stage Pipeline
Moderator: Joyce Cramer, President, Epilepsy Therapy Project
1:25-2:25 Panel
Public, Private Equity & Industry Perspectives on Financing New Therapies in Epilepsy & CNS:
Finding the Money in 2009
  Chair: Frank Fisher, President, Neuropace
Nicole Vitullo, Partner, Domain Associates
Omar Amirana, MD: Partner, Oxford Bioscience Partners LLC
Markus Goebel, MD, PhD, MBA, Partner, Novartis Venture Funds
Nancy Santilli, MSN, Director of Commercial Strategy, Endo Pharmaceuticals
2:25-2:40 Networking Break
Phase 1
2:40 Huperzine Harvard Steven Schachter, MD
2:50 NPY gene transfer Neurologix Christine Sapan
3:00 Neural Plasticity: 2DG NeuroGenomeX Thomas Sutula, MD, PhD
3:10 Drug Delivery Pump SierraNeuro Daniel Abrams, MD
3:20 Drug Delivery System New York University Orrin Devinsky, MD
3:30 Seizure detection/prevention NeuroVista John Harris, PhD
Pre-Clinical
3:40 New molecular entity NeuroTherapeutics Pharma Stephen Collins, MD, PhD
3:50 Galanin NTX 5055 Neuroadjuvants Steve Whit, PhD
4:00 AMP-X-001, 026 AurimMed Pharma Manny Balandrin, PhD
4:10 Magnetonanoparticles for MRI Epinano Massoud Akhtari, PhD
4:20 Intranasal lorazepam NanoCrystal Neurelis Craig Chambliss
4:30 Convection-enhanced toxin delivery MedGenesis Therapeutix Michael Rogawski, MD, PhD
4:40 GAERS, MTLE mouse models Synapcell Corrine Roucard, PhD
Closing Comments
4:50 The Role of Epilepsy Therapy Project in Supporting the Future Warren Lammert, Granitepoint Capital,
ETP Founder & Chairman

Contacts

Karen L. Bergman
BCC Partners
Tel: 650.575.1509

Joyce Cramer
Epilepsy Therapy Project
Tel: 203.799.0533

Our Mission

The mission of the Epilepsy Foundation is to lead the fight to overcome the challenges of living with epilepsy and to accelerate therapies to stop seizures, find cures, and save lives.

 
24/7 helpline
P